The experiment separated two interventions
Taaffe and colleagues studied 18 older men who first completed a period of progressive strength training. The men then received recombinant growth hormone or placebo while training continued. GH increased IGF-1 and changed lean and fat mass, but did not add a strength advantage. This was a GH trial, not a sermorelin trial. [1]
The design addresses a practical question: does adding a medicine improve on the gains available from the existing program? That is different from asking whether people become stronger while receiving both. A combined program can succeed even when only one part contributes to the outcome.
Why the lead-in period matters
The study included training before the drug comparison. [1] Our interpretation is that this makes the research especially relevant to claims about breaking through a training plateau. It avoids treating every early improvement after starting exercise as evidence of a medicine effect.
For a reader, the broader lesson is to examine what changed at the same time as treatment. A new exercise routine, different coaching and repeated testing can complicate a personal before-and-after story. A study that separates those influences provides a clearer answer than photographs or anecdotes from a package containing several interventions.
Lean mass and force are different outcomes
A scan-based body-composition result cannot substitute for a measured strength result. This trial is an example of why the two should be reported separately. [1] A headline saying “built muscle” may leave readers assuming better lifting performance even when the experiment did not demonstrate it.
Ask what measurement produced the claim. Was it a body-composition scan, a muscle biopsy, a force test or an everyday function such as climbing stairs? Each can be useful, but the choice changes what the result means. Our biomarker explanation applies the same reasoning to hormone measurements.
How to use this evidence responsibly
This experiment should not be used to calculate a sermorelin effect or declare the two treatments equivalent. Its value for a sermorelin reader is methodological: it exposes the gap between changing a biological measurement and adding a practical benefit. A specific sermorelin claim still needs appropriate evidence of its own.
If strength is your goal, ask the clinician which strength outcome the cited evidence measured and whether the benefit exceeded a relevant comparison. Discuss what a worthwhile change would mean for your activities, and how it would be assessed consistently. That conversation is more informative than selecting a treatment because it raises a hormone associated with muscle biology.
For tissue-level findings, see the muscle-biopsy experiment. Comparing those endpoints with force measurements makes it easier to see why the broad phrase muscle improvement needs a more exact definition.